Certara, Inc. (CERT)

14.93 +0.24 (+1.67%) As of 11:33AM EST. Market open.

Certara, Inc.

100 Overlook Center
Suite 101
Princeton, NJ 08540
United States
609 716 7900
https://www.certara.com

Sector(s): Healthcare
Industry: Health Information Services
Full Time Employees: 1,150

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. William F. Feehery Ph.D.	CEO & Director	1.35M	N/A	1971
Mr. Leif E. Pedersen	President & Chief Commercial Officer	625.53k	N/A	1965
Dr. Robert P. Aspbury Ph.D.	President of Certara Scientific Software	518.09k	N/A	1972
Dr. Patrick F. Smith Pharm.D.	President of Drug Development Solutions	621.58k	N/A	1971
Mr. John E. Gallagher III	Chief Financial Officer	N/A	N/A	1973
Mr. Max Kanevsky	Chief Technology Officer	N/A	N/A	N/A
Prof. Amin Rostami PharmD, Ph.D., FCP	Chief Scientific Officer	N/A	N/A	N/A
Mr. Richard M. Traynor	Senior VP, General Counsel & Secretary	N/A	N/A	1972
Mr. Ron DiSantis	Senior Vice President of Corporate Development	N/A	N/A	N/A
Ms. Sheila Rocchio MBA	Chief Marketing Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, the Netherlands, the Philippines, Poland, Portugal, Spain, Switzerland, and the United Kingdom. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Corporate Governance

Certara, Inc.’s ISS Governance QualityScore as of November 1, 2023 is 5. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 8; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.